ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,070,329,787 | -10.4% | 39,437,354 | +1.5% | 0.03% | -7.1% |
Q2 2023 | $1,194,181,249 | -12.6% | 38,847,796 | +2.4% | 0.03% | -20.0% |
Q1 2023 | $1,366,618,585 | -2.9% | 37,930,019 | +6.5% | 0.04% | -7.9% |
Q4 2022 | $1,408,010,301 | +0.3% | 35,627,791 | +1.9% | 0.04% | -7.3% |
Q3 2022 | $1,404,364,000 | +1.7% | 34,951,810 | +6.4% | 0.04% | +5.1% |
Q2 2022 | $1,381,172,000 | +11.3% | 32,853,776 | +3.1% | 0.04% | +34.5% |
Q1 2022 | $1,241,289,000 | +5.1% | 31,860,621 | +7.5% | 0.03% | +7.4% |
Q4 2021 | $1,181,017,000 | +8.8% | 29,636,565 | -1.3% | 0.03% | 0.0% |
Q3 2021 | $1,085,216,000 | +8.8% | 30,028,062 | +23.4% | 0.03% | +8.0% |
Q2 2021 | $997,787,000 | +1.6% | 24,342,200 | +8.1% | 0.02% | -7.4% |
Q1 2021 | $981,999,000 | +966.9% | 22,512,593 | +1124.2% | 0.03% | +800.0% |
Q4 2020 | $92,041,000 | +54.8% | 1,838,966 | +30.2% | 0.00% | +50.0% |
Q3 2020 | $59,440,000 | -11.5% | 1,412,886 | +2.1% | 0.00% | 0.0% |
Q2 2020 | $67,162,000 | – | 1,383,360 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |